Professor Daniel Hartson Provides In-depth Analysis of DLBCL’s Genetic Complexity and Innovative Research Models丨EHA 2025

Professor Daniel Hartson Provides In-depth Analysis of DLBCL’s Genetic Complexity and Innovative Research Models丨EHA 2025

2025.09.02
In 2025, the highly anticipated 30th European Hematology Association (EHA) Annual Congress was grandly held in Milan, Italy. This conference brought together top experts and scholars from around the world to discuss cutting-edge topics in basic research and clinical translation in the field of hematolog.Professor Daniel Hartson from the University of Cambridge delivered an insightful presentation on "Deciphering the Genomics of Aggressive Lymphoma." He systematically elaborated on the genetic complexity of Diffuse Large B-cell Lymphoma (DLBCL), shared his team's breakthrough achievements in constructing novel functional genomics models, and emphasized the critical importance of standardized molecular profiling for advancing future clinical research and personalized medicine.
Professor Rakesh Popat Elaborates on the Phase I Study Results of the Novel BCMA/GPRC5D/CD3 Trispecific Antibody丨EHA 2025

Professor Rakesh Popat Elaborates on the Phase I Study Results of the Novel BCMA/GPRC5D/CD3 Trispecific Antibody丨EHA 2025

2025.09.02
In 2025, the 30th Annual Congress of the European Hematology Association (EHA) was held in Milan, Italy. As a premier event in the global hematology field, this year's congress attracted thousands of experts and scholars from around the world, with nearly 4,000 abstracts submitted. Among the many studies, a Phase I clinical trial of the novel trispecific antibody JNJ-79635322 (JNJ-5322) (Abstract: S100) was selected by the congress presidency as one of six "outstanding and practice-changing" pivotal studies for an oral presentation during the plenary session, owing to its breakthrough efficacy. The study showcased the astounding potential of JNJ-5322 in treating patients with Relapsed/Refractory Multiple Myeloma (RRMM).